Skip Nav Destination
Imatinib is still recommended for frontline therapy for CML
A second-generation TKI should always be used as initial therapy for CML
Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)
Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms
HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment
Issue Archive
Table of Contents
POINT-COUNTERPOINT
Imatinib is still recommended for frontline therapy for CML
Clinical Trials & Observations
This article has a companion Counterpoint by Cortes.
A second-generation TKI should always be used as initial therapy for CML
Clinical Trials & Observations
This article has a companion Point by Hantel and Larson.
STIMULUS REPORT
CLINICAL TRIALS AND OBSERVATIONS
Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL
Clinical Trials & Observations
Arnon P. Kater,on behalf of the HOVON CLL study group.,Sabina Kersting,on behalf of the HOVON CLL study group.,Yvette van Norden,on behalf of the HOVON CLL study group.,Julie Dubois,on behalf of the HOVON CLL study group.,Johan A. Dobber,on behalf of the HOVON CLL study group.,Clemens H. Mellink,on behalf of the HOVON CLL study group.,Ludo M. Evers,on behalf of the HOVON CLL study group.,Fransien Croon-de Boer,on behalf of the HOVON CLL study group.,John Schreurs,on behalf of the HOVON CLL study group.,Ellen van der Spek,on behalf of the HOVON CLL study group.,Hein Visser,on behalf of the HOVON CLL study group.,Cecile Idink,on behalf of the HOVON CLL study group.,Shulamiet Wittebol,on behalf of the HOVON CLL study group.,Mels Hoogendoorn,on behalf of the HOVON CLL study group.,Sanne H. Tonino,on behalf of the HOVON CLL study group.,Mehrdad Mobasher,on behalf of the HOVON CLL study group.,Mark-David Levin,on behalf of the HOVON CLL study group.
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)
Clinical Trials & Observations
Gail J. Roboz,Sumithra J. Mandrekar,Pinkal Desai,Kristina Laumann,Alison R. Walker,Eunice S. Wang,Jonathan E. Kolitz,Bayard L. Powell,Eyal C. Attar,Wendy Stock,Clara D. Bloomfield,Jessica Kohlschmidt,Krzysztof Mrózek,Duane C. Hassane,Levi Garraway,Judit Jané-Valbuena,Michele Baltay,Adam Tracy,Guido Marcucci,Richard M. Stone,Richard A. Larson
Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas
Clinical Trials & Observations
Erin G. Reid,for the AIDS Malignancy Consortium,David Looney,for the AIDS Malignancy Consortium,Frank Maldarelli,for the AIDS Malignancy Consortium,Ariela Noy,for the AIDS Malignancy Consortium,David Henry,for the AIDS Malignancy Consortium,David Aboulafia,for the AIDS Malignancy Consortium,Juan Carlos Ramos,for the AIDS Malignancy Consortium,Joseph Sparano,for the AIDS Malignancy Consortium,Richard F. Ambinder,for the AIDS Malignancy Consortium,Jeannette Lee,for the AIDS Malignancy Consortium,Ethel Cesarman,for the AIDS Malignancy Consortium,Sara Yahyaei,for the AIDS Malignancy Consortium,Ronald Mitsuyasu,for the AIDS Malignancy Consortium,William Wachsman,for the AIDS Malignancy Consortium
MYELOID NEOPLASIA
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms
Clinical Trials & Observations
Raajit K. Rampal,John O. Mascarenhas,Heidi E. Kosiorek,Leah Price,Dmitriy Berenzon,Elizabeth Hexner,Camille N. Abboud,Marina Kremyanskaya,Rona Singer Weinberg,Mohamed E. Salama,Kamal Menghrajani,Vesna Najfeld,Lonette Sandy,Mark L. Heaney,Ross L. Levine,Ruben A. Mesa,Amylou C. Dueck,Judith D. Goldberg,Ronald Hoffman
PLATELETS AND THROMBOPOIESIS
TRANSFUSION MEDICINE
TRANSPLANTATION
HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment
Clinical Trials & Observations
-
Cover Image
Cover Image
COVER FIGURE
Cross section of a venous thrombus formed after ligation of the inferior vena cava in a mouse lacking the secretion regulator SNAP23 in its platelets. Thrombus size was markedly smaller than in control mice expressing SNAP23, but the remaining thrombus showed a platelet-containing, leukocyte-poor structure. The section was stained with CD41–fluorescein isothiocyanate (platelets, green), CD45-Alexa 568 (leukocytes, red), and DAPI (4′,6-diamidino-2-phenylindole, blue). See the article by Williams et al. - PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Advertisement intended for health care professionals